Our latest news

AbbVie is launching a US and Europe based golden ticket. The award consists of one golden ticket, which provides one year of fully paid individual bench, a desk and membership at one of BioLabs’ operating locations in the US, France or Germany. The award is intended for early-stage biotech companies developing therapeutics (not devices) in […]

Double success for Heidelberg life sciences: Two of the three prestigious Life Sciences Bridge Awards presented this year go to Heidelberg University’s Medical Faculty. The Aventis Foundation honors infectious disease specialist Dr. Frauke Mücksch and neurologist Dr. Varun Venkataramani for their groundbreaking research. While Mücksch is searching for new ways to one day cure HIV […]

Innovative imaging technique reveals hidden electrical connections in diseased hearts and provides new therapeutic approaches Cardiac fibrosis can be life-threatening: the formation of connective tissue in the heart muscle causes it to become stiffer, impairs electrical signal transmission, and weakens pumping capacity, which can lead to cardiac arrhythmias. However, the effects of cardiac fibrosis on […]

Got a startup idea? Curious about entrepreneurship? Then the GeneNovate program is the perfect place to start! Objective GeneNovate is the first nationwide entrepreneurship program in Germany, designed to empower innovators and entrepreneurs in the field of Gene and Cell Therapies (GCT), Biotech and Medicine. The program targets early-career scientists and physicians, such as advanced […]

Chicago, IL – October 8th, 2025 – VectorBuilder, a global leader in gene delivery technologies and CDMO services, today announced the publication of the miniVec plasmid system, engineered for safer, more efficient, and more scalable development of genetic medicines. The manuscript detailing this breakthrough is now published on BioRxiv. Plasmids have long been a key material […]

October 7, 2025 Celonic Group one of the leading “pureplay” Biologics CDMO, and The Carbogen Amcis Group, a leading pharmaceutical process development and Active Pharmaceutical Ingredient (API) manufacturing company, today announced a strategic partnership to offer a fully integrated Antibody-Drug Conjugate (ADC) development and manufacturing solution. The alliance combines Celonic’s advanced biologics capabilities with CARBOGEN […]

Chicago, IL – SEPTEMBER 30th, 2025 – VectorBuilder, a global leader in the gene delivery space, has won two prestigious awards at the Asia-Pacific Cell and Gene Therapy Excellence Awards 2025 (APCGTEA) and the Asia-Pacific Biologics CDMO Excellence Awards 2025 (APBCEA), hosted by IMAPAC. ● Best Cell & Gene Therapy Supplier Award – AAV Vector Manufacturing ● Best Gene […]

Since their discovery in 2004, the grid cells in the brain, which are important for our orientation, have been regarded as a kind of “GPS in the head.” However, scientists at the German Cancer Research Center (DKFZ) and Heidelberg University Hospital have now shown that grid cells work much more flexibly than previously assumed. In […]

Ladenburg, Germany, 25 September 2025 – Heidelberg Pharma AG (FSE: HPHA), a clinical-stage biotech company developing innovative Antibody Drug Conjugates (ADCs), today announced the initiation of Cohort 9 in its ongoing Phase I/IIa dose escalation trial of HDP-101, the Company’s lead ATAC candidate for the treatment of relapsed or refractory multiple myeloma. The Safety Review Committee […]